Atlas Trials

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Clinical trial NCT05546255 · UNKNOWN

Trial details

NCT number
NCT05546255
Sponsor
Chinese Academy of Medical Sciences
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2020-06-01
Primary completion
2022-12-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.